Andrew Uprichard, MD, has resigned from his position as president and chief of research and development (R&D) at EPIX Pharmaceuticals to pursue other opportunities.

The Lexington, Mass.-based company said it expects Uprichard to continue with the company as a consultant, likely to assist as EPIX continues efforts to gain FDA approval for its Vasovist blood-imaging agent. With Uprichard’s departure, EPIX intends to develop its R&D team with the addition of a clinical development professional.

Uprichard joined EPIX in 2004 and has served as president and head of research and development since 2006.